ALK expression is absent in pancreatic ductal adenocarcinoma
| Autor: | Dominik C. Bader, Michael Haas, Gerald Assmann, Stefan Boeck, Thomas Kirchner, Simone Reu, Eike Gallmeier, Axel Kleespies, Stephan Kruger, Steffen Ormanns, Volker Heinemann |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Oncology
Adult Male Cancer Research medicine.medical_specialty Pathology Pancreatic ductal adenocarcinoma endocrine system diseases Gene Expression hemic and lymphatic diseases Internal medicine Pancreatic cancer medicine Carcinoma Anaplastic lymphoma kinase Humans Anaplastic Lymphoma Kinase Aged Retrospective Studies Aged 80 and over Tissue microarray Hematology business.industry Receptor Protein-Tyrosine Kinases General Medicine Middle Aged medicine.disease Immunohistochemistry digestive system diseases Pancreatic Neoplasms Biomarker (medicine) Female business Carcinoma Pancreatic Ductal |
| Zdroj: | Journal of cancer research and clinical oncology. 140(9) |
| ISSN: | 1432-1335 |
| Popis: | It has not yet been clearly defined whether anaplastic lymphoma kinase (ALK) expression can be detected in pancreatic ductal adenocarcinoma (PDAC). Within a retrospective study, archival PDAC surgical specimens were screened for ALK expression in tumor and normal tissue by immunohistochemistry (IHC) with the use of a specific ALK detection kit on a tissue microarray (TMA). PDAC tumor tissue was available from 99 resected cases: fifty-eight out of 99 patients (59 %) had nodal-positive disease, and 80 patients (81 %) had pT3 tumors. Forty-nine patients underwent R0 resection, and in 48 cases, resection status was classified R1. Regarding ALK expression, five cases showed faint immunoreactivity on TMA, which was negative on whole mount sections. All other 94 cases showed no ALK expression. In 99 PDAC cases, no ALK expression was detected by IHC; ALK thus may not serve as a relevant drug target in PDAC. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink